Cellectar Biosciences, Inc. (NASDAQ: CLRB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Targeted Alpha Therapy Market, Drugs Approval, Proprietary Technologies & Clinical Trials: 20+ Drugs of Targeted Alpha Therapy In Clinical Trials [Yahoo! Finance]
Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its "market perform" rating re-affirmed by analysts at Oppenheimer Holdings Inc..
Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring
Cellectar Biosciences, Inc. (NASDAQ: CLRB) is now covered by analysts at LADENBURG THALM/SH SH. They set a "buy" rating and a $13.00 price target on the stock.